Orion’s and Bayer’s darolutamide shows substantial efficacy and a favourable safety profile in the treatment of prostate cancer in the ARAMIS trial

Suma Ramadas, PhD
Medical Affairs

Matthew Durham
Omnidynamic Marketing

Daniel Sontupe
Market Access

Brenda Snow
Authentic Patient Voice

Amy Giles
Increasing Engagement

Pat Purcell
Meeting Engagement

Liz Kane
Impactful Strategy

Bud Bilanich
Success Coach

Stacey Gandler
Brand Nourishment

Joey Cohen
Medication Adherence

Frank Burrell
Scientific Storytelling

Paul Theisen
Patient Acquisition

David Linetsky
Point-of-Care Marketing

Matt Turner
Patient Affordability